4a7b
From Proteopedia
(Difference between revisions)
												
			
			| (2 intermediate revisions not shown.) | |||
| Line 1: | Line 1: | ||
| ==MMP13 IN COMPLEX WITH A NOVEL SELECTIVE NON ZINC BINDING INHIBITOR CMPD22== | ==MMP13 IN COMPLEX WITH A NOVEL SELECTIVE NON ZINC BINDING INHIBITOR CMPD22== | ||
| - | <StructureSection load='4a7b' size='340' side='right' caption='[[4a7b]], [[Resolution|resolution]] 2.20Å' scene=''> | + | <StructureSection load='4a7b' size='340' side='right'caption='[[4a7b]], [[Resolution|resolution]] 2.20Å' scene=''> | 
| == Structural highlights == | == Structural highlights == | ||
| - | <table><tr><td colspan='2'>[[4a7b]] is a 2 chain structure with sequence from [ | + | <table><tr><td colspan='2'>[[4a7b]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4A7B OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4A7B FirstGlance]. <br> | 
| - | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=3W4:N-[(3R)-1,1-DIOXIDOTETRAHYDRO-2H-THIOPYRAN-3-YL]-4-(4-{[(3S)-3-HYDROXY-1-AZABICYCLO[2.2.2]OCT-3-YL]ETHYNYL}PHENOXY)BENZAMIDE'>3W4</scene>, <scene name='pdbligand=3W5:N-[(3S)-1,1-DIOXIDOTETRAHYDRO-2H-THIOPYRAN-3-YL]-4-(4-{[(3S)-3-HYDROXY-1-AZABICYCLO[2.2.2]OCT-3-YL]ETHYNYL}PHENOXY)BENZAMIDE'>3W5</scene>, <scene name='pdbligand=CA:CALCIUM+ION'>CA</scene>, <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=HAE:ACETOHYDROXAMIC+ACID'>HAE</scene>, <scene name='pdbligand=NA:SODIUM+ION'>NA</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene> | + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.2Å</td></tr> | 
| - | + | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=3W4:N-[(3R)-1,1-DIOXIDOTETRAHYDRO-2H-THIOPYRAN-3-YL]-4-(4-{[(3S)-3-HYDROXY-1-AZABICYCLO[2.2.2]OCT-3-YL]ETHYNYL}PHENOXY)BENZAMIDE'>3W4</scene>, <scene name='pdbligand=3W5:N-[(3S)-1,1-DIOXIDOTETRAHYDRO-2H-THIOPYRAN-3-YL]-4-(4-{[(3S)-3-HYDROXY-1-AZABICYCLO[2.2.2]OCT-3-YL]ETHYNYL}PHENOXY)BENZAMIDE'>3W5</scene>, <scene name='pdbligand=CA:CALCIUM+ION'>CA</scene>, <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=HAE:ACETOHYDROXAMIC+ACID'>HAE</scene>, <scene name='pdbligand=NA:SODIUM+ION'>NA</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr> | |
| - | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[ | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4a7b FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4a7b OCA], [https://pdbe.org/4a7b PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4a7b RCSB], [https://www.ebi.ac.uk/pdbsum/4a7b PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4a7b ProSAT]</span></td></tr> | 
| </table> | </table> | ||
| == Disease == | == Disease == | ||
| - | [ | + | [https://www.uniprot.org/uniprot/MMP13_HUMAN MMP13_HUMAN] Defects in MMP13 are the cause of spondyloepimetaphyseal dysplasia Missouri type (SEMD-MO) [MIM:[https://omim.org/entry/602111 602111]. A bone disease characterized by moderate to severe metaphyseal changes, mild epiphyseal involvement, rhizomelic shortening of the lower limbs with bowing of the femora and/or tibiae, coxa vara, genu varum and pear-shaped vertebrae in childhood. Epimetaphyseal changes improve with age.<ref>PMID:16167086</ref>   Defects in MMP13 are the cause of metaphyseal anadysplasia type 1 (MANDP1) [MIM:[https://omim.org/entry/602111 602111]. Metaphyseal anadysplasia consists of an abnormal bone development characterized by severe skeletal changes that, in contrast with the progressive course of most other skeletal dysplasias, resolve spontaneously with age. Clinical characteristics are evident from the first months of life and include slight shortness of stature and a mild varus deformity of the legs. Patients attain a normal stature in adolescence and show improvement or complete resolution of varus deformity of the legs and rhizomelic micromelia.<ref>PMID:19615667</ref>  | 
| == Function == | == Function == | ||
| - | [ | + | [https://www.uniprot.org/uniprot/MMP13_HUMAN MMP13_HUMAN] Degrades collagen type I. Does not act on gelatin or casein. Could have a role in tumoral process. | 
| <div style="background-color:#fffaf0;"> | <div style="background-color:#fffaf0;"> | ||
| == Publication Abstract from PubMed == | == Publication Abstract from PubMed == | ||
| Line 23: | Line 23: | ||
| ==See Also== | ==See Also== | ||
| - | *[[Matrix metalloproteinase|Matrix metalloproteinase]] | + | *[[Matrix metalloproteinase 3D structures|Matrix metalloproteinase 3D structures]] | 
| == References == | == References == | ||
| <references/> | <references/> | ||
| __TOC__ | __TOC__ | ||
| </StructureSection> | </StructureSection> | ||
| - | [[Category:  | + | [[Category: Homo sapiens]] | 
| - | [[Category:  | + | [[Category: Large Structures]] | 
| - | [[Category:  | + | [[Category: Gerhardt S]] | 
| - | [[Category:  | + | [[Category: Hargreaves D]] | 
Current revision
MMP13 IN COMPLEX WITH A NOVEL SELECTIVE NON ZINC BINDING INHIBITOR CMPD22
| 
 | |||||||||||
